Inactive Instrument

HUTCHISON CHINA MED. Share Price London S.E.

Equities

Pharmaceuticals

Sales 2024 * 688M 54.17B Sales 2025 * 847M 66.64B Capitalization 3.51B 276B
Net income 2024 * -107M -8.42B Net income 2025 * -1M -78.68M EV / Sales 2024 * 4.82 x
Net cash position 2024 * 199M 15.62B Net cash position 2025 * 306M 24.05B EV / Sales 2025 * 3.79 x
P/E ratio 2024 *
-31.1 x
P/E ratio 2025 *
421 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 52.37%
More Fundamentals * Assessed data
Dynamic Chart
Hutchmed (China) Chairman Resigns, Successor Named MT
Hutchmed China Simon To leaves role, succeeded by Dan Eldar AN
Hutchmed Announces Retirement of Simon To as Chairman, Names Dan Eldar Successor MT
HUTCHMED Limited Announces Executive Changes CI
Hutchmed (China) to Present Sovleplenib Phase III Data at EHA2024 Congress MT
HUTCHMED Limited Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to Be Presented at the Upcoming EHA2024 Congress CI
Transcript : HUTCHMED Limited Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM
Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies AN
Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer MT
HUTCHMED Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China CI
Hutchmed Starts Phase 2/3 Trials for Pancreatic Cancer Drug in China; Shares Rise 3% MT
Hutchmed Begins Phase 3 Trials for Leukemia Medication in China MT
HUTCHMED Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui CI
HUTCHMED Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024 CI
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug MT
More news
Managers TitleAgeSince
Chief Executive Officer 66 31/12/04
Director of Finance/CFO 57 30/06/08
Chief Tech/Sci/R&D Officer 59 31/12/21
Members of the board TitleAgeSince
Director/Board Member 73 28/02/17
Chairman 70 31/07/16
Director/Board Member 71 31/12/99
More insiders
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
More about the company